Sanofi annual ebitda
2022
2023
2024
2025
Sanofi EBITDA Growth & History (SAN)
Sanofi's calculated EBITDA was €12.48B for fiscal 2025.
View full Sanofi company overviewSanofi annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €12.48B | €1.49B | +13.57% |
| 2024 | 2024-12-31 | €10.99B | −€335.0M | −2.96% |
| 2023 | 2023-12-31 | €11.32B | −€2.19B | −16.19% |
| 2022 | 2022-12-31 | €13.51B | — | — |
Sanofi quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €1.68B | −€213.0M | −11.28% |
| Q1 2026 | 2026-03-31 | €2.72B | — | — |
| Q4 2025 | 2025-12-31 | −€341.0M | — | — |
| Q3 2025 | 2025-09-30 | €4.20B | — | — |
| Q2 2025 | 2025-06-30 | €1.89B | — | — |
Sanofi ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Sanofi's ebitda decreased from €13.51B to €12.48B, a change of −€1.03B. The latest reported quarter, Q2 2026, shows €1.68B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗Community posts
Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basi ...
